Analysis of elimination of non-self and development of Stealth T cells aiming generalized antigen-specific adoptive T cell therapy

• Project/Area Number: 15H04918
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: General surgery
• Research Institution: Nagasaki University (2016-2017); Mie University (2015)
• Principal Investigator: IKEDA Hiroaki 長崎大学, 医歯薬学総合研究科(医学系), 教授 (40374673)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000); Fiscal Year 2017: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2015: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
• Keywords: 細胞療法 / 遺伝子治療 / がん / 非自己細胞 / TCR / MHC / 癌 / T細胞輸注療法 / 免疫学 / がん免疫療法 / ゲノム編集 / siRNA

Outline of Final Research Achievements

We successfully generated 'Stealth T cells' that lack MHC class I expression as well as endogenous T cell receptor expression along with enforced expression of NY-ESO-1-specific T cell receptor utilizing beta 2 micro globulin-targetted CRISPR-Cas9 and siTCR vector. We showed that these 'Stealth T cells' lost the ability to stimulate allogeneic T cells while maintaining the anti-tumor activity against NY-ESO-1 positive tumors. These results suggested that 'Stealth T cells' will be useful for the adoptive T cell therapy with allogeneic T cells for cancer patients.

Research Products

• [Journal Article] Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers (2018)
  • Author(s): Tono Yasutaka、Ishihara Mikiya、Miyahara Yoshihiro、Tamaru Satoshi、Oda Hiroyasu、Yamashita Yoshiki、Tawara Isao、Ikeda Hiroaki、Shiku Hiroshi、Mizuno Toshiro、Katayama Naoyuki
  • Journal Title: Oncotarget Volume: 9 Issue: 19 Pages: 14909-14921
  • DOI: 10.18632/oncotarget.24504
  • Peer Reviewed / Open Access
• [Journal Article] Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination (2018)
  • Author(s): Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S.
  • Journal Title: Anticancer Research Volume: 38 Issue: 3 Pages: 1435-1444
  • DOI: 10.21873/anticanres.12368
  • Peer Reviewed / Open Access
• [Journal Article] Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination (2018)
  • Author(s): Abiko Takehiro、Tsuchikawa Takahiro、Miyauchi Kengo、Wada Masataka、Kyogoku Noriaki、Shichinohe Toshiaki、Miyahara Yoshihiro、Kageyama Shinichi、Ikeda Hiroaki、Shiku Hiroshi、Hirano Satoshi
  • Journal Title: Oncology Letters Volume: 15 Pages: 3703-3711
  • DOI: 10.3892/ol.2018.7767
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells (2018)
  • Author(s): Seo Naohiro、Shirakura Yoshitaka、Tahara Yoshiro、Momose Fumiyasu、Harada Naozumi、Ikeda Hiroaki、Akiyoshi Kazunari、Shiku Hiroshi
  • Journal Title: Nature Communications Volume: 9 Issue: 1 Pages: 435-435
  • DOI: 10.1038/s41467-018-02865-1
  • NAID: 120006532079
  • Peer Reviewed / Open Access
• [Journal Article] Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. (2017)
  • Author(s): Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H.
  • Journal Title: Blood Volume: 130 Issue: 18 Pages: 1985-1994
  • DOI: 10.1182/blood-2017-06-791202
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. (2017)
  • Author(s): Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ
  • Journal Title: Nat Commun. Volume: 8 Issue: 1 Pages: 14607-14607
  • DOI: 10.1038/ncomms14607
  • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
• [Journal Article] Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, Western blotting, and mRNA quantification. (2017)
  • Author(s): Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, HidaY, ShichinoheT, Tanaka E, Kaga K, Hatanaka K, MatsunoY, Imai N, Satoshi Hirano.
  • Journal Title: International Journal of Oncology Volume: 50 Issue: 1 Pages: 129-140
  • DOI: 10.3892/ijo.2016.3786
  • NAID: 120006313439
  • Peer Reviewed
• [Journal Article] Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. (2016)
  • Author(s): Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S.
  • Journal Title: Oncology Letters Volume: 12 Issue: 6 Pages: 4493-4504
  • DOI: 10.3892/ol.2016.5253
  • NAID: 120005981404
  • Peer Reviewed / Open Access
• [Journal Article] T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. (2016)
  • Author(s): Ikeda H
  • Journal Title: International Immunology Volume: 28 Issue: 7 Pages: 349-353
  • DOI: 10.1093/intimm/dxw022
  • Peer Reviewed / Open Access
• [Journal Article] Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination (2016)
  • Author(s): Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S.
  • Journal Title: Immunotherapy Volume: 印刷中 Issue: 5 Pages: 527-40
  • DOI: 10.2217/imt-2016-0007
  • Peer Reviewed
• [Journal Article] Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes. (2015)
  • Author(s): Ikeda H, Shiku H.
  • Journal Title: Cancer Immunology, Immunotherapy Volume: 64 Issue: 7 Pages: 903-909
  • DOI: 10.1007/s00262-015-1718-0
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer (2015)
  • Author(s): Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H.
  • Journal Title: Clinical Cancer Research Volume: in press Issue: 10 Pages: 2268-2277
  • DOI: 10.1158/1078-0432.ccr-14-1559
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] 2015 Guidance on cancer immunotherapy development in early-phase clinical studies (2015)
  • Author(s): Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer
  • Journal Title: Cancer Sci Volume: 106 Issue: 12 Pages: 1761-1771
  • DOI: 10.1111/cas.12819
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Presentation] がん免疫療法の未来 ～免疫チェクポイント阻害療法の先に～ (2017)
  • Author(s): 池田裕明
  • Organizer: 第２７回サイトメトリー学会
  • Invited
• [Presentation] 2.Extended applications of cancer immunotherapy with engineered T cells. (2017)
  • Author(s): Hiroaki Ikeda
  • Organizer: The 36th Sapporo International Cancer Symposium
  • Int'l Joint Research / Invited
• [Presentation] 遺伝子改変細胞を用いた免疫療法の実用化に向けて (2017)
  • Author(s): 池田裕明
  • Organizer: 第２１回日本がん免疫学会学術総会
  • Invited
• [Presentation] がんのT細胞療法 (2017)
  • Author(s): 池田裕明
  • Organizer: 第５５回日本がん治療学会学術集会
  • Invited
• [Presentation] 10.Development of TCR gene therapy with allogeneic “Stealth T cells” deficient in ndogenous TCR and HLA class I molecules. (2017)
  • Author(s): Okada S, Yasui K, Okamoto S, Mineno J, Tasesako K, Shiku H, Eguchi S, Ikeda H.
  • Organizer: 第46回日本免疫学会学術集会
• [Presentation] Development of TCR-like scFv CAR that recognizes MAGE-A4230-239/HLA-A*02:01 (2017)
  • Author(s): Yasushi Akahori, Yuya Kato, Yoshihiro Miyahara, Chisaki Amaike, Wang Linam, Takuma Kato, Hiroaki Ikeda, Hiroshi Shiku
  • Organizer: 第76回 日本癌学会学術総会
• [Presentation] NY-ESO-1 TCR遺伝子改変T細胞輸注におけるサイトカイン放出症候群発症と臨床反応 (2017)
  • Author(s): 北野滋久、石原幹也、宮原慶裕、影山慎一、加藤栄史、三輪秀行、山本昇、岩瀬弘明、服部浩佳、船越建、小島隆嗣、池田裕明、渡辺隆、珠玖洋
  • Organizer: 第２１回日本がん免疫学会学術総会
• [Presentation] がん精巣抗原MAGE-A4由来ペプチドp230-239をHLA-A*02:01拘束性に認識するTCR様抗体を使用したCARによるがん抑制作用の検討 (2017)
  • Author(s): 赤堀泰、加藤裕也、宮原慶裕、天池千咲、王立楠、加藤琢磨、池田裕明、珠玖洋
  • Organizer: 第２１回日本がん免疫学会学術総会
• [Presentation] NY-ESO-1を標的とするTCR遺伝子改変T細胞輸注療法における安全性の基礎的検討と輸注細胞動体及び血清学的解析 (2017)
  • Author(s): 宮原慶裕、北野滋久、石原幹也、影山慎一、加藤栄史、三輪秀行、山本昇、岩瀬弘明、服部浩佳、船越建、小島隆嗣、池田裕明、渡辺隆、珠玖洋
  • Organizer: 第２１回日本がん免疫学会学術総会
• [Presentation] Cytokine Release Syndrome and Tumor Responses in a First-in-Man Trial of a Novel Affinity-Enhanced TCR-Gene Transduced T Cell Transfer Targeting NY-ESO-1 Antigen (2017)
  • Author(s): Kageyama S, Ishihara M, Kitano S, Miyahara Y, Kato H, Mishima H, Yamamoto N, Hattori H, Iwase H, Funakoshi T, Kojima T Inoue N, Kidokoro T, Tomura D, Okamoto S, Chono H, Nukaya I, Mineno J, Ikeda H, Watanabe T, Shiku H
  • Organizer: 2017 米国血液学会総会
  • Int'l Joint Research
• [Presentation] Cytokine release syndrome and tumor responses in a first-in-man trial of a novel affinity-enhanced TCR-gene transduced T cell transfer targeting NY-ESO-1 antigen (2017)
  • Author(s): Hiroyoshi Hattori, Mikiya Ishihara, Shigehisa Kitano, Yoshihiro Miyahara, Hidefumi Kato, Hideyuki Mishima, Noboru Yamamoto, Hiroaki Iwase, Takeru Funakoshi, Takashi Kojima, Hiroaki Ikeda, Takashi Watanabe, , Shinichi Kageyama, Hiroshi Shiku
  • Organizer: 2017 ESGCT
  • Int'l Joint Research
• [Presentation] Clinical trials of NY-ESO-1 and MAGE-A4 targeting TCR-gene transduced T cell transfer to patients with refractory solid tumors (2017)
  • Author(s): Shinichi Kageyama, Mikiya Ishihara, Shigehisa Kitano, Yoshihiro Miyahara, Hidefumi Kato, Hideyuki Mishima, Noboru Yamamoto, Hiroaki Iwase, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Hiroaki Ikeda, Takashi Watanabe, Hiroshi Shiku
  • Organizer: 第２３回 日本遺伝子細胞治療学会学術集会
  • Invited
• [Presentation] がん免疫療法開発のガイダンス2016～がん免疫療法に用いる細胞製品の品質、非臨床試験の考え方～ (2017)
  • Author(s): 池田裕明
  • Organizer: 厚生労働省医薬品等審査迅速化事業費補助金 革新的医薬品・医療機器・再生医療製品実用化促進事業 公開シンポジウム がん免疫療法2017 －複合化と個別化の科学基盤とレギュレーション－
  • Place of Presentation: 東京大学 伊藤謝恩ホール（東京都・文京区)
  • Invited
• [Presentation] ネオアンチゲン等の新たながん免疫療法の標的 (2017)
  • Author(s): 池田裕明
  • Organizer: 厚生労働省医薬品等審査迅速化事業費補助金 革新的医薬品・医療機器・再生医療製品実用化促進事業 公開シンポジウム がん免疫療法2017 －複合化と個別化の科学基盤とレギュレーション－
  • Place of Presentation: 東京大学 伊藤謝恩ホール（東京都・文京区)
  • Invited
• [Presentation] Tumor-Specific Donor Lymphocyte Infusion for Tumor Relapse after MHC-Haploidentical Hematopoietic Stem Cell Transplantation (2016)
  • Author(s): Isao Tawara, Kana Okamori, Naoyuki Katayama, Hiroshi Shiku, Hiroaki Ikeda.
  • Organizer: The 58th American Society of Hematology Annual Meeting & Exposition
  • Place of Presentation: San Diego, CA, USA
  • Year and Date: 2016-12-03
  • Int'l Joint Research
• [Presentation] Efficacy and safety of immunotherapy with chimeric antigen receptor targeting WT1 and HLA-A24:02 pMHC complex (2016)
  • Author(s): Hiroaki Ikeda, Yasushi Akahori, Motohiro Yoneyama, Yuki Orito, Yoshihiro Miyahara, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno, Kazutoh Takesako, Hiroshi Fujiwara, Masaki Yasukawa, Hiroshi Shiku
  • Organizer: 米国遺伝子細胞治療学会
  • Place of Presentation: Washigton DC, USA
  • Year and Date: 2016-05-04
  • Int'l Joint Research
• [Presentation] がんに対するT細胞輸注療法の新展開 (2016)
  • Author(s): 池田裕明
  • Organizer: 第53回日本臨床分子医学会学術集会
  • Place of Presentation: 東京国際フォーラム（東京都・千代田区）
  • Invited
• [Presentation] 同種移植後再発の成人T細胞白血病リンパ腫に対するT細胞レセプター遺伝子導入ドナーリンパ球輸注療法 (2016)
  • Author(s): 池田裕明
  • Organizer: 第3回日本HTLV-1学会
  • Place of Presentation: 鹿児島県市町村自治会館（鹿児島県・鹿児島市）
  • Invited
• [Presentation] がんに対する遺伝子改変T細胞輸注療法の臨床開発 (2016)
  • Author(s): 池田裕明
  • Organizer: 第75回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜（神奈川県・横浜市）
  • Invited
• [Presentation] 癌の治癒を目指すＴ細胞輸注療法 (2016)
  • Author(s): 池田裕明
  • Organizer: 第２９回日本バイオセラピィ学会学術集会総会
  • Place of Presentation: 久留米シティプラザ（福岡県・久留米市）
  • Invited
• [Presentation] T 細胞輸注療法~遺伝子改変 T 細胞療法を中心に~ (2015)
  • Author(s): 池田裕明
  • Organizer: 第148回日本医学会シンポジウム
  • Place of Presentation: 日本医師会館（東京都・文京区）
  • Year and Date: 2015-12-24
  • Invited
• [Presentation] Immunotherapy with chimeric antigen receptor targeting intracellular WT1 gene product complexed with HLA-A*24:02 molecule (2015)
  • Author(s): Hiroaki Ikeda, Yasushi Akahori, Motohiro Yoneyama, Yuki Orito, Yoshihiro Miyahara, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno, Kazutoh Takesako, Hiroshi Fujiwara, Masaki Yasukawa, Hiroshi Shiku
  • Organizer: 57th ASH Annual Meeting and Exposition
  • Place of Presentation: Orlando, USA
  • Year and Date: 2015-12-05
  • Int'l Joint Research
• [Presentation] 遺伝子改変T細胞輸注による新たながん治療 New era of cancer immunotherapy with gene-engineered T cells (2015)
  • Author(s): 池田裕明
  • Organizer: 第５３回日本癌治療学会学術集会
  • Place of Presentation: 国立京都国際会館（京都市・左京区）
  • Year and Date: 2015-10-29
  • Invited
• [Presentation] 癌治癒を目指すT細胞輸注療法の新展開 New era of adoptive T cell therapy forward the cure of cancer patients (2015)
  • Author(s): 池田裕明
  • Organizer: 第７４回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場（愛知県・名古屋市）
  • Year and Date: 2015-10-08
  • Invited
• [Presentation] Clinical development of TCR gene-therapy for patients with epithelial cancer and leukemia (2015)
  • Author(s): Ikeda H
  • Organizer: 第21回日本遺伝子治療学会学術集会
  • Place of Presentation: 大阪国際会議場（大阪府・大阪市）
  • Year and Date: 2015-07-24
  • Invited
• [Presentation] Immunotherapy with antigen receptor engineered lymphocytes 「抗原受容体遺伝子導入リンパ球輸注療法」 (2015)
  • Author(s): Hiroaki Ikeda
  • Organizer: 第１３回 日本臨床腫瘍学会学術集会
  • Place of Presentation: ロイトン札幌（札幌市・中央区）
  • Year and Date: 2015-07-16
  • Invited
• [Presentation] Development of immunotherapy with chimeric antigen receptor targeting intracellular WT1 gene product presented on HLA-A*24:02 molecule (2015)
  • Author(s): Yasushi Akahori, Motohiro Yoneyama, Hiroaki Ikeda, Yuki Orito, Yoshihiro Miyahara, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno, Kazutoh Takesako, Hiroshi Fujiwara, Masaki Yasukawa, Hiroshi Shiku
  • Organizer: がん免疫療法・マクロファージ国際会議 2015
  • Place of Presentation: 東京大学（東京都・文京区）
  • Year and Date: 2015-07-09
  • Int'l Joint Research
• [Presentation] Donor lymphocyte infusion thrapy utilizing genetically engineered lymphocytes that express tumor-specific TCR and siRNA for endogenous TCR enables tumor eradication without GvHD induction. (2015)
  • Author(s): Ikeda H, Ueno H, Tawara I, Kawamura A, Okamori K, Imai N, Okamoto S, Mineno J, Takesako K, Katayama N, Shiku H.
  • Organizer: 13th Annual Meeting of Association of Cancer Immunotherapy (CIMT).
  • Place of Presentation: Mainz, Germany
  • Year and Date: 2015-05-12
  • Int'l Joint Research
• [Book] 固形がんに対するT細胞輸注療法（Ｔ細胞輸注法シリーズ4）、がん免疫療法 (2018)
  • Author(s): 池田裕明
  • Total Pages: 84
  • Publisher: メディカルビュー社
• [Book] ネオ抗原に対するT細胞輸注療法（Ｔ細胞輸注法シリーズ３）、がん免疫療法 (2018)
  • Author(s): 池田裕明
  • Total Pages: 84
  • Publisher: メディカルビュー社
• [Book] TCR遺伝子改変T細胞療法、 最新医学 (2018)
  • Author(s): 池田裕明
  • Total Pages: 146
  • Publisher: 最新医学社
• [Book] CAR-T細胞療法の進展（Ｔ細胞輸注法シリーズ２）、 がん免疫療法 (2017)
  • Author(s): 池田裕明
  • Total Pages: 90
  • Publisher: メディカルビュー社
• [Book] Ｔ細胞を利用したがん免疫療法、 医学のあゆみ (2017)
  • Author(s): 池田裕明
  • Total Pages: 143
  • Publisher: 医歯薬出版株式会社
• [Book] Personalized Medicineとしてのがん免疫療法、 遺伝子医学MOOK31 がん免疫療法 (2017)
  • Author(s): 池田裕明
  • Total Pages: 287
  • Publisher: ㈱メディカルドウ
• [Book] 遺伝子改変T細胞を用いた免疫、 がん分子標的治療 (2017)
  • Author(s): 池田裕明
  • Total Pages: 108
  • Publisher: メディカルビュー社
• [Book] Ｔ細胞受容体遺伝子改変技術を用いたがん治療 (2017)
  • Author(s): 池田裕明
  • Total Pages: 79
  • Publisher: 癌と化学療法社
• [Book] Ｔ細胞輸注療法の歴史（Ｔ細胞輸注法シリーズ１）、 がん免疫療法 (2017)
  • Author(s): 池田裕明
  • Total Pages: 72
  • Publisher: メディカルビュー社
• [Book] T細胞輸注療法の歴史 がん免疫療法 (2017)
  • Author(s): 池田裕明
  • Publisher: メディカルレビュー社
• [Book] T細胞輸注朗報(TIL療法，TCR-T療法). がん免疫療法 腫瘍免疫学の最新知見から治療法のアップデートまで 実験医学増刊 (2016)
  • Author(s): 池田裕明
  • Publisher: 羊土社
• [Book] 複合的がん免疫療法.免疫療法が効かないがんについての考察と展望 Cancer Board がん免疫療法時代の航海図 (2016)
  • Author(s): 池田裕明
  • Publisher: 医学書院
• [Book] 細胞療法．細胞 The CELL． (2016)
  • Author(s): 池田裕明
  • Publisher: ニューサイエンス社
• [Book] 腫瘍特異的T細胞受容体(TCR)遺伝子導入T細胞療法 医薬ジャーナル4月号 (2016)
  • Author(s): 池田裕明
  • Publisher: 医薬ジャーナル社
• [Book] TIL/TCR遺伝子導入T細胞の養子免疫療法 医学のあゆみ (2016)
  • Author(s): 池田裕明
  • Publisher: 医歯薬出版株式会社
• [Book] 遺伝子改変T細胞を用いるがん免疫療法 躍進するがん免疫療法 ファルマシア (2016)
  • Author(s): 池田裕明
  • Publisher: 日本薬学会
• [Book] TCR改変T細胞による食道がん治療 今、着実に実り始めた遺伝子治療ー最新研究と今後の展開ー 遺伝子医学MOOK (2016)
  • Author(s): 池田裕明．玖珠 洋
  • Publisher: メディカルドウ
• [Book] 薬剤学 がん治療ワクチンの可能性 (2016)
  • Author(s): 池田裕明、原田直純
  • Total Pages: 74
  • Publisher: 日本薬剤学会
• [Book] 医学のあゆみ TIL/TCR遺伝子導入T細胞の養子免疫療法 (2016)
  • Author(s): 池田裕明
  • Publisher: 医歯薬出版株式会社
• [Book] T細胞を用いた養子がん免疫療法の現状と展望 (2015)
  • Author(s): 池田裕明
  • Total Pages: 56
  • Publisher: メディカル・サイエンス・ダイジェスト ニューサイエンス社
• [Book] 実験医学 最新がん免疫療法 （遺伝子改変T細胞を利用したがん免疫療法 がん患者の「治癒」をめざして） (2015)
  • Author(s): 池田裕明
  • Publisher: 羊土社
• [Remarks] 三重大学大学院医学系研究科 遺伝子・免疫細胞治療学
  • URL: http://shikuken.jp/